In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma. Building on these findings, this study aims to conduct a multi-center prospective observational study to evaluate the prognostic value of the circulating lymphocyte CD4/CD8 ratio in nasopharyngeal carcinoma patients prior to treatment.
Study Type
OBSERVATIONAL
Enrollment
325
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
Progression Free Survival
The time from the first diagnosis of nasopharyngeal carcinoma to the first observation of disease progression or death from any cause
Time frame: 3 Years
Overall Survival
The time from the first diagnosis of nasopharyngeal carcinoma to the occurrence of death from any cause
Time frame: 3 Years
Distant Metastasis-free Survival
Distant metastasis-free survival (DMFS) was defined as the time from diagnosis to the occurrence of distant metastasis or the date of censoring, whichever came first.
Time frame: 3 years
Locoregional Recurrenc-free Survival
Locoregional recurrence-free survival (LRRFS) was defined as the time from diagnosis to the occurrence of locoregional recurrence or the date of censoring, whichever came first.
Time frame: 3 Years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.